tbuckley/cabot-search huggingface dataset:
AB0984 BIOLOGICAL THERAPIES IN JUVENILE IDIOPHATIC ARTHRITIS: ARE THERE ANY DIFFERENCES BETWEEN CATEGORIES?
Authors: A. García Fernández, A. Briones-Figueroa, L. Calvo Sanz, Á. Andreu-Suárez, J. Bachiller-Corral, A. Boteanu
Journal: Annals of the Rheumatic Diseases (2020)

Background: Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of pediatric diseases. Different response to biological treatment (BT) has been reported according to disease subtype. Objectives: To analyze the prescription and withdrawal of BT in JIA patients with focus on JIA category. Methods: A retrospective observational study was conducted on JIA patients followed in a referal hospital and who had received at least one BT between 1999 and 2019. Results: 130 JIA patients were analyzed: 29 (22,4%) were Oligoarticular Persistent (OligP), 22 (16,9%) Enthesitis related Arthritis (ERA), 20 (15,4%) Systemic (sJIA), 19 (14,6%) Polyarticular RF- (PolyRF-), 14 (10,8%) Polyarticular RF+(PolyRF+), 13 (10%) Oligoarticular-Extended (OligE), 11 (8,4%) Psoriatic Arthritis (APso) and 2 (1,5%) Undifferentiated (Und). The main characteristics are summarized in table 1. The first line BT most frequently indicated was Etanercept up to 40% in all the categories except for ERA, where the most frequent BT was Adalimumab and sJIA, where the most frequent BT was Anakinra. The time between diagnosis and start of BT was different among the categories (p=0,007). In the Und category, the time until BT was the shortest (median: 1 month), since both patients had coxitis, followed by APso [median: 9 months IQR(1-57)] and sJIA [median: 17,5 months IQR(0,3-146,8)]. The survival of the first BT was different among the categories (p=0,006): 94,7% of the ERA continue receiving the first BT, followed by 76,2% of OligP and 50% of PolyRF+ and APso. Only 42% of sJIA continue on the first BT prescribed [up to 53,3% were TNF inhibitors (TNFi)]. The categories with less retention of the first BT were: OligE (25%); PolyRF- (27,3%) and Und (0%). The most frequent cause of discontinuation, among these categories, was secondary failure. In the survival analysis between categories, there were differences on OligP (p=0,004), OligE (p=0,042) and PolyRF- (p=0,017). Tocilizumab and Adalimumab were the BT with highest survival with regards to Infliximab, Etanercept, Rituximab (OligE, PolyRF-), Abatacept (OligE, PolyRF-) and Certolizumab (OligP). The survival rate of IL1 inhibitiors and IL6 inhibitiors was higher regarding to TNFi in sJIA patients (p=0,013). Conclusion: Taking into account JIA category is mandatory to choose BT and to understand the response and discontinuation of BT. OligE and PolyRF - showed a high rate of change of the first BT related to secondary failure of Etanercept and Infliximab when compared to Adalimumab and Tocilizumab, as described in the survival analysis. The category with the highest retention of the first BT was ERA. UND patients started sooner BT due to the presence of coxitis. In sJIA, IL1 inhibitors and IL6 inhibitors were superior to TNFi in the survival analysis, as reported in existing literature. Table: Disclosure of Interests: None declared
The Importance of Proper Death Certification During the COVID-19 Pandemic
Authors: James R. Gill, Maura E. DeJoseph
Journal: JAMA (2020)

Rishi K. Wadhera, MD, MPP, MPhil; Priya Wadhera, MD, MS; Prakriti Gaba, MD; Jose F. Figueroa, MD, MPH; Karen E. Joynt Maddox, MD, MPH; Robert W. Yeh, MD, MSc; Changyu Shen, PhD
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
Authors: Bachar Samra, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Nicholas J. Short
Journal: Journal of Hematology & Oncology (2020)

Recent years have witnessed major advances that have improved outcome of adults with acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual disease has fine-tuned our prognostic models and guided our treatment decisions. The treatment paradigms of ALL have been revolutionized with the advent of tyrosine kinase inhibitors targeting BCR-ABL1, monoclonal antibodies targeting CD20 (rituximab), antibody-drug conjugates targeting CD22 (inotuzumab ozogamicin), bispecific antibodies (blinatumomab), and CD19 chimeric antigen receptor T cell therapy (tisagenlecleucel). These highly effective new agents are allowing for novel approaches that reduce reliance on intensive cytotoxic chemotherapy and hematopoietic stem cell transplantation in first remission. This comprehensive review will focus on the recent advances and future directions in novel therapeutic strategies in adult ALL.
Disseminated Xanthosiderohistiocytosis With Monoclonal Gammopathy—A Rare Form of Xanthoma Disseminatum
Authors: Laura Iglesias-Girard, Simon F. Roy, Hugo Chapdelaine, Delphine Désy, Danielle Bouffard, Deana Funaro
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Can Infections Cause Alzheimer Disease?
Authors: Anthony L. Komaroff
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of tumor-associated lymphocytes as a predictor of response to neoadjuvant chemotherapy in breast cancer: Results from the GeparDuo and GeparTrio trial
Authors: C. Denkert, S. Loibl, A. Noske, B. M. Müller, R. Kronenwett, J. Budczies, C. von Törne, K. Engels, C. Solbach, G. von Minckwitz
Journal: Journal of Clinical Oncology (2009)

11054 Background: Preclinical investigations suggest an involvement of the immune system in chemotherapy response; however, this contribution has not been validated in prospective clinical trials so far. Methods: We investigated the inflammatory infiltrate in a total of 1058 pretherapeutic breast cancer core biopsies from two neoadjuvant anthracycline-taxane-based studies. As a training cohort, we used 218 core biopsies from the GeparDuo study. The results were validated in a completely independent cohort of 840 samples from the GeparTrio study. In addition, molecular parameters of lymphocyte recruitment and activation in breast cancer tissue were evaluated by kinetic PCR. Results: While the overall rate of pathological complete response (pCR) in the GeparDuo cohort was 12.8%, it was significantly increased to 42.7% in the tumors with more than 60% intratumoral or stromal lymphocytes. In a multivariate regression analysis, the percentage of intratumoral lymphocytes (iTu-Ly) was an independent significant parameter for pCR (P = 0.013) in the GeparDuo cohort. In the validation set from the GeparTrio trial, the inflammatory infiltrate was a strong predictor of pCR in univariate (P &lt; 0.0005) and multivariate logistic regression (P &lt; 0.0005). For tumors with 60% iTu-Ly the pCR rate was 40% with an odds ratio (OR) of 8.5 (4.0–18.2) which were similar to those values in hormone receptor negative samples (pCR: 36%; OR: 6.0 [4.0–9.1]). The expression of inflammatory marker genes and chemokines related to B and T infiltration in tumor tissue was significantly linked to the presence of a lymphocytic infiltrate and mRNA expression data showed a significant association of T cell markers with a pCR (P &lt; 0.003). Conclusions: An increased lymphocytic inflammatory infiltrate in breast cancer is a new independent predictor of response to anthracyclin-taxane neoadjuvant chemotherapy and might be helpful to identify patients with benefit from cytotoxic chemotherapy. [Table: see text]
Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care &amp; Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association
Authors: Margaret A. Powers, Joan K. Bardsley, Marjorie Cypress, Martha M. Funnell, Dixie Harms, Amy Hess-Fischl, Beulette Hooks, Diana Isaacs, Ellen D. Mandel, Melinda D. Maryniuk, Anna Norton, Joanne Rinker, Linda M. Siminerio, Sacha Uelmen
Journal: Diabetes Care (2020)

Diabetes is a complex and challenging disease that requires daily self-management decisions made by the person with diabetes. Diabetes self-management education and support (DSMES) addresses the comprehensive blend of clinical, educational, psychosocial, and behavioral aspects of care needed for daily self-management and provides the foundation to help all people with diabetes navigate their daily self-care with confidence and improved outcomes (1,2).

The prevalence of diagnosed diabetes is projected to increase in the U.S. from 22.3 million (9.1% of the total population) in 2014, to 39.7 million (13%) in 2030, and to 60.6 million (17%) in 2060 (3). Approximately 90–95% of those with diabetes have type 2 diabetes (4). Diabetes is an expensive disease, and the medical costs of health care alone for a person with diabetes are 2.3 times more than for a person without diabetes (5). Confounding the diabetes epidemic and high costs, therapeutic targets are not being met (6). There is a lack of improvement in reaching clinical target goals since 2005 despite advancements in medication and technology treatment modalities. Indeed, between 2010 and 2016 improved outcomes stalled or reversed (6).

The goals of this Consensus Report are to improve clinical care and education services, to improve the health of individuals and populations, and to reduce diabetes-associated per capita health care costs (1,7). This article is specifically directed toward health care providers (physicians, nurse practitioners, physician assistants [PAs]), referred to herein as providers, as it outlines the benefits of DSMES, defines four critical times to provide and modify DSMES (see Fig. 1), proposes how to locate DSMES-related resources, and discusses potential solutions to access and utilization barriers. This report provides guidance to others as well: health systems and organizations can use this report to anticipate and address the needs of persons with …
Minimally Invasive Surgery for Gynecologic Cancers—A Cautionary Tale
Authors: Amer Karam, Oliver Dorigo
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract B26: A novel dietary advanced glycation end product (AGE) model to assess impact on tumor progression
Authors: Reid K. Schuster, Bradley A. Krisanits, Jamie Randise, Lourdes M. Nogueira, Kristi Helke, Amanda C. LaRue, David P. Turner, Victoria J. Findlay
Journal: Cancer Research (2020)

Abstract Advanced glycation end products, or AGEs, and their corresponding receptor, the receptor for AGE (RAGE), have roles in several chronic diseases such as diabetes and cardiovascular disease due to their proinflammatory properties. Recently AGE: RAGE signaling has been implicated in a number of cancers, including prostate and breast cancer; however, how AGE: RAGE signaling effects these cancers has not been elucidated. To examine this, we have developed a novel dietary AGE tumor model. Our regular and AGE (TestDiet DIO 58G7) diets consist of equal %k/cal from fat, protein, and carbohydrate; however, the predominant source of carbohydrate in the control diet is starch and in the AGE diet is sugar. To generate the high-AGE diet we autoclave at 120°C for 15 min. In the high-AGE diet, the autoclaving mimics the cooking process in foods and induces the formation of AGEs, allowing us to observe the effects of chronic AGE consumption on both normal developmental processes as well as tumor formation and progression. Specifically, we have been able to show the impact of this diet during time periods where the breast is more susceptible to chronic AGE consumption, namely the “windows of susceptibility.” Additionally, we have applied this novel dietary model to the RAGE null (-/-) mice to explore the role of AGE:RAGE signaling further. Specifically, we have shown that chronic consumption of a high-AGE diet disrupts normal pubertal growth in the mammary gland through the recruitment of aberrant stroma, including fibroblasts and macrophages, and that these aberrant changes persist into adulthood. We further show that dietary AGEs promote aggressive tumor growth through manipulation of the tumor microenvironment and that this is RAGE dependent. We propose that this dietary model can be used as an in vivo method to examine the impact of dietary AGEs on the TME and as a mechanism for potential therapeutic and preventative strategies. Citation Format: Reid K. Schuster, Bradley A. Krisanits, Jamie Randise, Lourdes M. Nogueira, Kristi Helke, Amanda C. LaRue, David P. Turner, Victoria J. Findlay. A novel dietary advanced glycation end product (AGE) model to assess impact on tumor progression [abstract]. In: Proceedings of the AACR Special Conference on the Evolving Landscape of Cancer Modeling; 2020 Mar 2-5; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2020;80(11 Suppl):Abstract nr B26.
Benzene induces rapid leukemic transformation after prolonged hematotoxicity in a murine model
Authors: Jianxin Zhao, Pinpin Sui, Bo Wu, Aili Chen, Yedan Lu, Fenxia Hou, Xiurong Cheng, Shiwei Cui, Jiayang Song, Gang Huang, Caihong Xing, Qian-fei Wang
Journal: Leukemia (2020)
Photothermal conversion-coordinated Fenton-like and photocatalytic reactions of Cu2-xSe-Au Janus nanoparticles for tri-combination antitumor therapy
Authors: Yuanlin Wang, Zhenglin Li, Ying Hu, Jing Liu, Mengyu Guo, Hengxiang Wei, Shanliang Zheng, Tingting Jiang, Xiang Sun, Zhuo Ma, Ye Sun, Flemming Besenbacher, Chunying Chen, Miao Yu
Journal: Biomaterials (2020)
AB0426 FIBROSING INTERSTITIAL LUNG DISEASE IN PRIMARY SJOGREN SYNDROME
Authors: A. Manfredi, C. Vacchi, G. Della Casa, S. Cerri, G. DI Cecco, F. Coppi, F. Luppi, C. Salvarani, M. Sebastiani
Journal: Annals of the Rheumatic Diseases (2020)

Background: Interstitial lung disease (ILD) represents the most frequent pulmonary manifestation of primary Sjogren’s syndrome (pSS), with a prevalence ranging between 6-70% in different retrospectives studies. Non-specific interstitial pneumonia (NSIP) is recognized as the most common ILD disorder, followed by organizing pneumonia (OP), usual interstitial pneumonia (UIP) and lymphocytic interstitial pneumonia (LIP), specifically associated with pSS but less frequent. Objectives: To investigate the prevalence of fibrosing patterns in a monocentric cohort of pSS patients evaluated for lung involvement in a cross-sectional study. Methods: In a cross-sectional study all patients fulfilling ACR/EULAR classification criteria for pSS and with a known diagnosis of ILD were enrolled; the other patients were carefully investigated for signs or symptoms suggestive for ILD (including the search for velcro crackles with a digital device); when suspect, patients underwent to high resolution computed tomography (HRCT). An expert radiologist re-evaluated all HRCT for classifying the ILD pattern as: UIP, fibrotic NSIP, fibrotic OP, NSIP, OP, LIP, indeterminate. Results: One hundred and eighty-five pSS patients were enrolled; among them 34 showed ILD (18.4%) with the following features: M/F 3/31, median age 57 (range 24-80), median FVC 90% (39-127%), median DLCO 49% (20-84%). Patients were classified in two groups according to radiologic classification: the group 1 (18 pts 52,9%) included UIP (13 patients, 38.2%), fibrotic NSIP (4, 11.8%), fibrotic OP (1 2.9%); the group 2 (16 pts, 47.1%) included NSIP (6, 17.6%), OP (4, 11.8%), indeterminate (4, 11.8%), LIP (2, 5.9%). No significant differences were observed between the two groups with the exception of anti-SSB positivity more frequently detected in non-fibrosing pattern (p 0 , 043 ). Conclusion: Despite previous observations, our data suggest a high prevalence of fibrosing ILD pattern in pSS patients. We participate at a multidisciplinary team with expert pulmonologists and radiologists and some patients of our cohort firstly referred to pulmonologist for appearance of ILD before the diagnosis of pSS, contributing to the possible selection of more severe lung disease. However, these data suggest first of all that pSS should always be considered in differential diagnosis of fibrosing ILD; moreover, since fibrosing ILD is thought to have a worse response to immunosuppressive drugs, the role of new possible therapeutic strategies such as anti-fibrotic could represent an important field of interest. Disclosure of Interests: None declared
Abstract PHA04: A new somatic engineering-based model of small-cell lung cancer development
Authors: Kee-Beom Kim, Dong-Wook Kim, Kwon-Sik Park
Journal: Cancer Research (2020)

Abstract Defining the cancer genome is essential for understanding the pathogenesis, but it remains challenging due to the paucity of robust models for characterizing recurrent mutations found in cancer. To understand the molecular mechanisms underlying the development of small-cell lung cancer (SCLC), an aggressive type of lung cancer initiated by inactivation of both RB and P53, it is important to determine the functional impact of recurrent mutations found in the patient tumors. To this end, we developed a somatic engineering approach, using a CRISPR/Cre hybrid tool that expresses guide RNA, Cas9 endonuclease, and Cre recombinase from a single adenoviral vector (Ad-target of gRNA-CRISPR/Cre). Intratracheal instillation of this recombinant virus causes mutation in a candidate tumor suppressor gene while recombining floxed alleles of Rb1, Trp53, and Rbl2 in the same epithelial cell. To determine functions of Ep300, Slit2, and Fhit, whose orthologous genes are frequently mutated in SCLC patient tumors, we infect the Rb1/Trp53/Rbl2 conditional mice with the viral vectors carrying gRNAs against these genes. The mice infected with Ad-Ep300-CRISPR/Cre or Ad-Fhit-CRISPR/Cre have higher tumor burden in the lungs than those infected with Ad-lacZ-CRISPR/Cre used as control. Although Slit2 is significantly mutated in SCLC, the mice infected with Ad-Slit2-CRISPR/Cre do not increase tumor burden relative to those with Ad-lacZ-CRISPR/Cre. These results for the first time validate the oncogenic impact of Ep300 and Fhit mutations. This study demonstrates the feasibility and robustness of a new somatic engineering-based model for characterizing candidate mutations, which will facilitate the discovery of key oncogenic drivers and pathways from the large number of novel somatic alterations in SCLC. Ongoing efforts with this new approach are focused on validation of functionally unknown mutations alone or in combinations. This abstract is also being presented as Poster A39. Citation Format: Kee-Beom Kim, Dong-Wook Kim, Kwon-Sik Park. A new somatic engineering-based model of small-cell lung cancer development [abstract]. In: Proceedings of the AACR Special Conference on the Evolving Landscape of Cancer Modeling; 2020 Mar 2-5; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2020;80(11 Suppl):Abstract nr PHA04.
Association of Neighborhood-Level Disadvantage With Alzheimer Disease Neuropathology
Authors: W. Ryan Powell, William R. Buckingham, Jamie L. Larson, Leigha Vilen, Menggang Yu, M. Shahriar Salamat, Barbara B. Bendlin, Robert A. Rissman, Amy J. H. Kind
Journal: JAMA Network Open (2020)

Social determinants of health, such as income, education, housing quality, and employment, are associated with disparities in Alzheimer disease and health generally, yet these determinants are rarely incorporated within neuropathology research.
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Authors: Jason Fangusaro, Olaf Witt, Pablo Hernáiz Driever, Asim K Bag, Peter de Blank, Nadja Kadom, Lindsay Kilburn, Robert M Lober, Nathan J Robison, Michael J Fisher, Roger J Packer, Tina Young Poussaint, Ludmila Papusha, Shivaram Avula, Alba A Brandes, Eric Bouffet, Daniel Bowers, Anton Artemov, Murali Chintagumpala, David Zurakowski, Martin van den Bent, Brigitte Bison, Kristen W Yeom, Walter Taal, Katherine E Warren
Journal: The Lancet Oncology (2020)
Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity
Authors: Luke Mountjoy, Sinto Sebastian, Tania Jain, Talal Hilal, Miguel Gonzalez-Velez, Marlene Girardo, Greg Ahmann, Jeremy Larsen, Leif Bergsagel, Rafael Fonseca
Journal: Leukemia (2020)
Exploring and visualizing large-scale genetic associations by using PheWeb
Authors: Sarah A. Gagliano Taliun, Peter VandeHaar, Andrew P. Boughton, Ryan P. Welch, Daniel Taliun, Ellen M. Schmidt, Wei Zhou, Jonas B. Nielsen, Cristen J. Willer, Seunggeun Lee, Lars G. Fritsche, Michael Boehnke, Gonçalo R. Abecasis
Journal: Nature Genetics (2020)